Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib - Pharming (NASDAQ:PHAR)

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21,

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,Japan ,Australia ,London ,City Of ,United Kingdom ,Canada ,United States ,America ,Heather Robertson ,Eveline Wu ,Michael Levitan ,Claire Dobbs ,Anurag Relan ,Ethan Metelenis ,Pharming Groupnv ,European Medicines Agency ,Vp Investor Relations Corporate Communications ,Lifespring Life Sciences Communication ,University Of North Carolina School Medicine ,Linkedin ,Exchange Commission ,Drug Administration ,Pharming Group ,Investor Relations Corporate Communications ,Division Chief ,Paediatric Rheumatology ,Associate Professor ,North Carolina School ,Chief Medical Officer ,Activated Phosphoinositide ,North America ,Middle East ,Annual Report ,Allergy Clin ,Rev Allergy ,Investor Relations ,Corporate Communications ,Spring Life Sciences Communication ,